News & Updates
Filter by Specialty:
Benralizumab appears superior to mepolizumab in severe eosinophilic asthma
Both mepolizumab and benralizumab are effective in improving the clinical outcomes of patients with severe eosinophilic asthma, as shown in a recent study. However, treatment with benralizumab appears to be better than mepolizumab in reducing exacerbations, improving forced expiratory volume, and depleting blood eosinophils.
Benralizumab appears superior to mepolizumab in severe eosinophilic asthma
12 Dec 2023
Exenatide in acutefor stroke fails to improve neurological outcomes but helps manage blood sugar safely
In the treatment of patients with acute ischaemic stroke, treatment with exenatide does not appear to have any beneficial effect on neurological function at 7 days but is safe and substantially decreases the frequency of hyperglycaemic events, without leading to hypoglycaemia, according to the results of the phase II TEXAIS trial.
Exenatide in acutefor stroke fails to improve neurological outcomes but helps manage blood sugar safely
12 Dec 2023
Amivantamab-based regimens may alter EGFR-mutant NSCLC treatment paradigm in Asia
Updates from two MARIPOSA trials presented at ESMO Asia 2023 underpin the potential of amivantamab-based regimens for the treatment of locally advanced or metastatic EGFR-mutated non-small cell lung cancer (EGFRm NSCLC) in Asian subgroups.
Amivantamab-based regimens may alter EGFR-mutant NSCLC treatment paradigm in Asia
11 Dec 2023
Myeloma patients may benefit from mezigdomide-dexamethasone doublet
In a study evaluating heavily pretreated patients with relapsed and refractory multiple myeloma (R/R MM), the combination of mezigdomide and dexamethasone showed promising preliminary efficacy, with myelosuppression and infection as primary toxicities.
Myeloma patients may benefit from mezigdomide-dexamethasone doublet
08 Dec 2023
How does combination therapy fare as second-line treatment for NSCLC with EGFR mutation?
Combination therapy does not appear to have beneficial effects in terms of progression-free survival (PFS), overall response rate (ORR), disease control rate (DCR), and incidence of adverse events compared with monotherapy in patients with advanced nonsmall cell lung cancer (NSCLC) who failed first-line treatment with an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor, a study has shown.